cjc 1295 with/ipamorelin CJC-1295 and Ipamorelin Peptide Injection CJC-1295 + Ipamorelin | GH

Clinical Weight Loss Results In a 12-week randomized clinical trial involving 300 obese adults, subjects receiving 1 mg daily of AOD-9604 lost an average of 2.6 kg compared to 0.8 kg in the placebo group

CJC-1295 binds the GHRH receptor (GHRH-R), a Gs-coupled GPCR on anterior pituitary somatotrophs, raising intracellular cAMP and triggering PKA-mediated GH transcription and release

Most side effects are mild and temporary, typically resolving within days to weeks

While research in this area is ongoing, it remains to be determined whether healthy subjects may receive anabolic benefit from increased GH and IGF-1 [11]

Administration and injection technique IGF-1 LR3 can be administered subcutaneously or intramuscularly